Select a news story to see related coverage from other media outlets.
Inspired by his mother's severe knee pain, Hyderabad pharmacist Surya Maguluri co-founded Litemed to develop Curapod, a wearable light-therapy device for chronic pain relief. Since its launch, over 30,000 units have been sold, with more than 200,000 pain management sessions recorded. Curapod aims to provide safe, daily pain relief without side effects, addressing issues faced by people with prolonged standing or sitting, and offering an alternative to frequent painkiller use.
We measured how 2 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (75/100). Lens Score 38/100 — moderate-to-low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
The articles present a straightforward narrative focusing on a medical innovation without political framing. They highlight the founder's personal motivation and the product's impact, reflecting a neutral, human-interest perspective. There is no evident political viewpoint or partisan framing in the coverage.
The tone across the articles is positive and hopeful, emphasizing the potential benefits of the Curapod device for chronic pain sufferers. The coverage highlights innovation and personal motivation, with no negative or critical sentiment, creating an encouraging portrayal of the startup's efforts.
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.
| Source | Their headline | Bias | Sentiment |
|---|---|---|---|
| indianexpress | Spurred by his mother's knee pain, this Hyderabad pharmacist built a wearable for chronic pain relief | Center | Positive |
| indianexpress | Spurred by his mother's knee pain, this Hyderabad pharmacist built a wearable for chronic pain relief | Center | Positive |
indianexpress broke this story on 31 May, 10:34 am. Other outlets followed.
Story is receiving appropriate media attention relative to public interest.
Institutions and figures named across source coverage.
